secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041838
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q2 2023 net loss $18.7M; cash $74.6M; expands Celltrion partnership
--------------------------------------------------------------------------------

- Net loss of $18.7M for Q2 2023, up from $16.0M in Q2 2022; cash and securities $74.6M (down from $98.5M at YE 2022).
- Expanded Celltrion partnership to develop RT-105 (adalimumab biosimilar) using high-capacity RaniPill HC device.
- Appointed Kate McKinley as Chief Business Officer, bringing 20 years of biopharma experience.
- Plan to initiate Phase 2 for RT-102 and Phase 1 for RT-111 (monoclonal antibody) in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023041838/0000950170-23-041838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023041838/rani-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer